Buzz Stocks: Adamis Pharmaceuticals Corp, ProNAi Therapeutics Inc, and Juno Therapeutics Inc

U.S. stocks are poised to rally out of the gate, with all eyes focused on an upcoming speech from Fed Chair Janet Yellen. Among equities in focus today are biotech stocks Adamis Pharmaceuticals Corp (NASDAQ:ADMP), ProNAi Therapeutics Inc (NASDAQ:DNAI), and Juno Therapeutics Inc (NASDAQ:JUNO). 

• ADMP is bracing for a 44% drop out of the gate, after the U.S. Food and Drug Administration (FDA) rejected the drugmaker's emergency epinephrine syringe and requested additional testing. The stock, which closed at $8.86 on Friday, hasn't suffered a percentage loss that big in seven years. Fortunately for options traders, the pace of put buying has been accelerated in recent months, albeit amid relatively light absolute volume. Adamis Pharmaceuticals Corp's 50-day put/call volume ratio of 0.16 across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) ranks in the high 85th annual percentile.

• In other unfortunate drug news, DNAI has suspended the development of its lymphoma cancer treatment, due to disappointing trial data. After settling last week at $6.38 -- and being halted earlier -- the stock is poised to open at a record low, down 53% in electronic trading. This may have ProNAi Therapeutics Inc short sellers kicking rocks for not holding out longer. During the most recent reporting period, short interest on the drug stock plummeted roughly 25%, and just 4% of DNAI's float is now sold short.

• On the other hand, JUNO is up 6.2% pre-market, after the firm's CAR-T therapy candidate produced high response rates in adult patients with acute lymphoblastic leukemia (ALL). According to Juno Therapeutics Inc CEO Hans Bishop, these patients are now being enrolled in a mid-stage trial of its JCAR015 treatment -- which he believes "will support accelerated approval," potentially as early as 2017. Should the stock gap higher at the open, the shares would be back in positive year-to-date territory, after closing last week at $43.90 -- just pennies shy of breakeven. Meanwhile, analysts have been firmly planted in JUNO's bullish corner, with seven brokerages handing out a "buy" or better rating, compared to one "hold" and not a single "sell."

Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!